Minoxidil

Generic Name: Minoxidil

Brand Names: Loniten, Minox, Regoxidine, Rogaine

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₅N_₅O

CAS Number: 38304-91-5

Unique Ingredient Identifier: 5965120SH1

Background: A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.

Indication: For the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.

Associated Conditions: Androgenetic Alopecia (AGA), Severe, symptomatic Hypertension

Associated Therapies: -

Clinical Trials

Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia

Phase 2

Recruiting

Conditions: Androgenetic Alopecia

Interventions: Drug: Finasteride
Drug: Minoxidil

First Posted Date: 2023-08-14

Last Posted Date: 2023-09-22

Lead Sponsor: Indonesia University

Target Recruit Count: 40

Registration Number: NCT05990400

Locations: 🇮🇩
University Indonesia, Jakarta, Other (Non U.s.), Indonesia

Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia

Phase 1

Not yet recruiting

Conditions: Androgenetic Alopecia

Interventions: Drug: Minoxidil

First Posted Date: 2023-05-18

Last Posted Date: 2023-05-18

Lead Sponsor: Aneira Pharma, Inc.

Target Recruit Count: 14

Registration Number: NCT05864885

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

Early Phase 1

Recruiting

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Endocrine Therapy-Induced Alopecia
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage I Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8

Interventions: Drug: Minoxidil
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2022-06-14

Last Posted Date: 2024-05-31

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 50

Registration Number: NCT05417308

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

Phase 2

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Minoxidil

First Posted Date: 2022-03-09

Last Posted Date: 2023-10-05

Lead Sponsor: Loyola University

Target Recruit Count: 34

Registration Number: NCT05272462

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia

Phase 4

Conditions: Androgenetic Alopecia

Interventions: Drug: Minoxidil
Drug: Cetirizine

First Posted Date: 2020-03-03

Last Posted Date: 2020-03-04

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT04293822

Locations: 🇪🇬
Assiut University, Assiut, Egypt

Treatment Results for Patients with Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study

Phase 4

Recruiting

Conditions: Central Centrifugal Cicatricial Alopecia (CCCA)

Interventions: Drug: Topical steroid class I-II
Drug: Doxycyline
Drug: Triamcinolone Acetonide
Drug: Minoxidil

First Posted Date: 2019-12-23

Last Posted Date: 2024-10-02

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 250

Registration Number: NCT04207931

Locations: 🇺🇸
Wake Forest Baptist Health Department of Dermatology, Winston-Salem, North Carolina, United States

Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure

Not Applicable

Completed

Conditions: Anal Fissure

Interventions: Drug: Minoxidil
Drug: Glyceryl trinitrate

First Posted Date: 2018-05-18

Last Posted Date: 2019-10-07

Lead Sponsor: Mansoura University

Target Recruit Count: 62

Registration Number: NCT03528772

Locations: 🇪🇬
Mansoura university hospital, Mansourah, Dakahlia, Egypt

ENERGI-F701 for Female Hair Loss Treatment

Phase 2

Completed

Conditions: Hair Loss
Female Pattern Baldness
Alopecia

Interventions: Drug: ENERGI-F701
Drug: Regaine

First Posted Date: 2017-11-22

Last Posted Date: 2020-11-24

Lead Sponsor: Energenesis Biomedical Co., Ltd.

Target Recruit Count: 67

Registration Number: NCT03351322

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan

Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients

Phase 3

Conditions: Female Pattern Alopecia

Interventions: Drug: Saline
Drug: Minoxidil

First Posted Date: 2012-08-01

Last Posted Date: 2013-09-25

Lead Sponsor: Brasilia University Hospital

Target Recruit Count: 60

Registration Number: NCT01655108

Locations: 🇧🇷
University of Brasilia, Brasilia, Distrito Federal, Brazil

Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia

Phase 2

Completed

Conditions: Androgenetic Alopecia

Interventions: Drug: Minoxidil
Drug: vehicle of 5% Minoxidil topical foam

First Posted Date: 2011-03-21

Last Posted Date: 2013-11-07

Lead Sponsor: Natalie GARCIA BARTELS

Target Recruit Count: 70

Registration Number: NCT01319370

Locations: 🇩🇪
Charité-Universitätsmedizin Berlin, Clinical Research Center for Hair and Skin Science, Dept. of Dermatology, Venereology and Allergy, Berlin, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy